Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Complex Interaction of Drugs, Viruses and the Immune System

Paulo R. Criado MD¹, João Avancini MD¹, Claudia G. Santi MD¹, Ana T. Amoedo Medrado MD², Carlos E. Rodrigues MD³ and Jozélio F. de Carvalho MD⁴

¹Dermatology Department, Hospital das Clínicas of the Faculty of Medicine, University of São Paulo, São Paulo, Brazil
²Instituto de Medicina Especializada (IMME), feira de Santana, Bahia, Brazil
³Medicine Department, University of Fortaleza-Unifor, Ceará, Brazil
⁴Rheumatology Division, Hospital Universitário Prof. Edgard Santos, Federal University of Bahia, School of Medicine, Salvador, Bahia, Brazil

ABSTRACT: The DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), also known as DIHS (drug-induced hypersensitivity syndrome), presents clinically as an extensive mucocutaneous rash, accompanied by fever, lymphadenopathy, hepatitis, hematologic abnormalities with eosinophilia and atypical lymphocytes, and may involve other organs with eosinophilic infiltration, producing damage in several systems, especially kidney, heart, lungs, and pancreas. The pathogenesis is related to specific drugs (especially the aromatic anticonvulsants), altered immune response, sequential reactivation of herpes virus, and association with some HLA alleles. Glucocorticoids are the basis for the treatment of the syndrome, which may be given with intravenous immunoglobulin and, in selected cases, ganciclovir. This article reviews current concepts regarding the interaction of drugs, viruses and immune responses during this complex adverse-drug reaction.

KEY WORDS: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), drug-induced hypersensitivity syndrome (DIHS), exanthema, herpes virus, hepatitis, nephritis

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also known as drug-induced hypersensitivity syndrome (DIHS), described for the first time in 1936, presents clinically as an extensive mucocutaneous rash, accompanied by fever, lymphadenopathy, hepatitis, hematologic abnormalities with eosinophilia and atypical lymphocytes, and may involve other organs with resultant damage in several systems [1].

The incidence ranges between 1 in 1000 and 1 in 10,000 exposures [2,3]. Adults are more affected than children, and although the precise incidence of drug reaction has not yet been determined, it is much more common than Stevens-Johnson syndrome, which has an incidence of 1.2–6 cases per million persons-year, and most cases are sporadic, with no gender predilection. Recognition of this syndrome is of paramount importance, since the mortality rate is about 10%–20% and a specific therapy may be necessary [1].

ETIOPATHOGENESIS

The exact mechanism of DRESS/DIHS remains to be determined but, in cases related to anticonvulsant drugs, three components are considered: a) deficiency or abnormality of the epoxide hydroxylase enzyme that detoxifies the metabolites of aromatic amine anticonvulsants (metabolic pathway), b) associated sequential reactivation of herpes virus family, and c) ethnic predisposition with certain human leukocyte antigen alleles (immune response) [4].

DRUGS INVOLVED AND METABOLISM

This type of reaction is most commonly seen with seven different drug groups:

- anticonvulsants, such as the aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), mexiletine, lamotrigine, valproate, ethosuximide, zonisamide
- antidepressants (desipramine, amitriptyline, fluoxetine)
- sulfonamides and sulfones (dapsone, sulfasalazine, trimethoprim-sulfamethoxazole, salosulphopyridine)
- anti-inflammatory drugs (piroxicam, naproxen, diclofenac, sundilac, phenylbutazone, ibuprofen)
- anti-infectives (abacavir, cidofovir, terbinfina, nevirapine, minocycline, linezolid, doxycycline, telaprevir, nitrofurantoin, zalcitabine, spiramycin, metronidazole, pipercillin-tazobactam, ceftriaxone)
- angiotensin-converting enzyme inhibitors (captopril, enalapril)
- beta-blockers (atenolol, celiprolol)
Aromatic anticonvulsants are metabolized by the oxidation system of cytochrome P450 (CYP) in ane trees. In some cases, these metabolites can act as a danger signal and induce the pathways of co-stimulatory signals on antigen-presenting cells.

Neonate antigenes can be presented via the human histocompatibility complex class I (HLA-DR) or class II (HLA-A, B, or C), to CD4 or CD8 T cells.

Reactive intermediate metabolites act as a danger signal and induce the pathways of co-stimulatory signals on antigen-presenting cells.

It was demonstrated that carbamazepine, valproic acid and amoxicillin are able to exert immunomodulatory actions by inhibiting histone decaboixlase on B lymphocytes, producing a hypogammaglobulinemia that precedes the clinical onset of DRESS/DIHS.

The clonal expansion of T cells requires sequential reactivation of latent herpes virus, and at the same time CD8+ T cells are produced, which can cause cellular damage generating danger signs that can stimulate resting T cells, inducing co-stimulatory pathways.

There is a migration of CD4+ cells to the lungs. Also, the production of IL-4 and IL-5 by CD4+ cells and IL-17 by CD4+Th17+ cells causes tissue and peripheral eosinophilia.

HHV-6 can be detected only in patients with DRESS/DIHS, but other herpes viruses such as HHV-7, Epstein-Barr virus and cytomegalovirus can be reactivated during the course of DRESS/DIHS.

Results obtained with polymerase chain reaction analysis showed that various herpes viruses are sequentially reactivated during the course of DRESS/DIHS in most patients. The cascade of viral reactivation is initiated by EBV or HHV-6 and extends over a period, followed by HHV-7 reactivation and eventually CMV proliferation. In some patients, the clinical manifestations of this syndrome persist despite withdrawal of the offending drug.

Although there are conflicting views on the pathogenesis of DRESS/DIHS in different parts of the world, recent studies have suggested a close relationship between human herpes virus 6 and the development of DRESS/DIHS. Sporadic reports have shown that not only HHV-6, but also other herpes viruses such as HHV-7, Epstein-Barr virus and cytomegalovirus can be reactivated during the course of DRESS/DIHS.

Several clinical similarities that can be observed between DRESS/DIHS and infectious mononucleosis suggest a possible range of viruses as triggers for this syndrome. In addition, this syndrome has unique features that are not necessarily typical of a drug reaction. These include: a) late onset in relation to introduction of the causative medication, b) clinical signs and laboratory values suggesting a viral infection, and c) episodes of exacerbation, despite withdrawal of the offending drug.

Although there are conflicting views on the pathogenesis of DRESS/DIHS in different parts of the world, recent studies have suggested a close relationship between human herpes virus 6 and the development of DRESS/DIHS. Sporadic reports have shown that not only HHV-6, but also other herpes viruses such as HHV-7, Epstein-Barr virus and cytomegalovirus can be reactivated during the course of DRESS/DIHS.

The reactivation of HHV-6 is evidenced by increased levels of immunoglobulin-G anti-HHV-6 DNA, and HHV-6 is commonly found in the second or third week after the rash onset, despite the high variability of clinical manifestations among patients with this drug reaction.

Since the reactivation of HHV-6 can be detected only in patients with DRESS/DIHS, but not other adverse drug reactions, as observed in a Japanese study,
DRESS/DIHS is an entity distinct from other serious adverse drug reactions due to the dynamic changes in the immune response observed during the course of the disease. The phenotype of circulating CD4+ T cells is changed to CD8+ phenotype at the time of viral reactivation. Regulatory T cells are initially increased in number in the circulation and skin, but decrease, in parallel, in functional deterioration of the different organs or systems.

Although the terms DRESS and DIHS are often and mistakenly used interchangeably, it is currently believed that DIHS represents the most severe cases of DRESS, with reactivation of HHV-6 detected in a large majority of patients and only in a limited number of patients with DRESS [18,19].

HISTOPATHOLOGY

Histopathology of the skin shows a diffuse dense or superficial and perivascular lymphocytic infiltrate. Eosinophils in the dermis or swelling may or not be present [Figure 3A]. Sometimes
there is a band-like infiltrate with atypical lymphocytes simulating epidermotropism mycosis fungoides [20].

Fernando et al. [21] described a patient with DRESS/DIHS triggered by carbamazepine; a biopsy of the rash revealed an unusual form of superficial perivascular inflammatory infiltrate, in which tiny granulomas along with a moderate number of lymphocytes were observed.

Thus, biopsies of organs involved in DRESS/DIHS, such as skin and liver, in a significant number of patients may demonstrate the true frequency of granulomatous infiltration in the disease and help us understand the pathogenesis of the reaction [21].

**SYMPTOMS AND SIGNS**

The syndrome usually develops within 2 months after drug introduction, more often 3 weeks to 3 months after the introduction of the drug, or less if the drug is readministered [8]. Fever, often high (38–40°C), which is the most common symptom (seen in 90–100% of cases), and rash (87% of cases) are the first signs, especially when related to antiepileptic drugs [22,23-27]. The cutaneous eruption consists of a morbilliform rash, which is indistinguishable from the rash of other less severe reactions [Figure 3 B and C). The face, upper trunk and upper extremities are affected initially, occurring in about 90% of cases, with subsequent progression to the lower extremities, and an erythrodermic rash may develop [5].

The maculopapular eruption later becomes infiltrated with edematous follicular accentuation. Swelling of the face, with marked periorbital involvement, is a clue to the diagnosis, occurring in about 25% of patients, and can be so intense that the patient becomes disfigured. Over time the rash becomes purplish on the lower limbs and the result is scaling [5,25]. Another form of presentation is exfoliative dermatitis, which may be associated with mucosal involvement, such as cheilitis, erosions, pharygitis and enanthematous enlarged tonsils [20,28]. Bilateral edema and infiltration of the salivary glands with xerostomia has been reported frequently [22].

Lymphadenopathy is common (70–75% of cases), limited to the lymph nodes or generalized and painful, gradually resolving with withdrawal of the drug [22].

Various hematologic abnormalities are present, including marked leukocytosis, eosinophilia (30% of cases) and atypical lymphocytes similar to mononucleosis [20,22]. These findings guide the diagnosis toward DRESS; however, it may sometimes be difficult to distinguish it from viral infections such as Epstein-Barr virus or hematologic diseases.

Leukocytosis may be high, up to 50,000 leukocytes/mm³, and eosinophilia reaches higher than 20,000/mm³ [20]. The eosinophilia may determine the involvement of internal organs with pulmonary infiltrates. In general, eosinophilia may be observed about 1 to 2 weeks after the onset of the syndrome or may even occur after the increase in liver enzymes has normalized [29]. Hemophagocytic syndrome is rarely observed in the course of DRESS/DIHS and is associated with and triggered by various conditions, including viral infections, particularly EBV, malignant tumors, or autoimmune diseases.

Multiorgan involvement may include a wide variety of organs and systems with myocardiitis/myositis, pericarditis, interstitial nephritis (11% of cases), necrotizing granulomatous vasculitis in kidney, brain involvement (encephalitis or meningitis), colitis and thyroiditis [20,29].

Liver involvement is the most common visceral manifestation (50–60% of patients), the second being lymphadenopathy. Hepatomegaly may constitute a finding on physical examination. Hepatitis with isolated elevation of liver transaminases is common (51% of cases), usually anicteric, but liver failure is the leading cause of death [20].

Although pulmonary involvement is rarely reported in DRESS/DIHS, interstitial pneumonia with eosinophilia is often observed among patients in whom the syndrome was triggered by minocycline [22]. Myocarditis may develop at the start of the syndrome or up to 40 days after emergence of the drug reaction. Neurological complications include meningitis and encephalitis. Meningoencephalitis occurs about 2 to 4 weeks after onset of the drug reaction, and may lead to coma, seizures, headaches and disorders of speech, and paresis and paralysis of the cranial nerve [29].

Gastrointestinal bleeding may be an acute complication caused by ulcers due to CMV. Endoscopic examination reveals arterial bleeding from gastric ulcerations [29].

Kennebeck [30] documented the frequency of clinical manifestations and laboratory data of the anticonvulsant hypersensitivity syndrome: fever (90–100%), cutaneous eruption (87–90%), lymphadenopathy (70%), hepatitis (50–60%), hematologic abnormalities (23–50%), periorbital
and orofacial edema (25%), myalgia and arthritis (20%), nephritis (11%), pharyngitis (10%) and pulmonary manifestations (9%).

The exclusion of other serious infections – particularly bacteremia, neoplastic diseases (lymphoma, leukemia, hypereosinophilic syndrome, paraneoplastic), autoimmune or connective tissue conditions (adult-onset Still’s disease, lupus erythematosus, vasculitis) – is necessary for an accurate diagnosis of DRESS/DIHS [22,31,32].

The mortality rate can reach 20%, especially in cases with advanced age, renal impairment, jaundice and hepatitis with reactivation of CMV.

**DIAGNOSTIC CRITERIA**

The diagnosis is difficult since the clinical features may be incomplete or less characteristic, for example, hepatitis without rash, or merely a pulmonary infiltrate with eosinophilia. Bocquet, Bagot and Roujeau [20] were the first to propose criteria for the diagnosis of DRESS. According to these authors the diagnosis can be established if there are at least three criteria present:

- drug rash
- hematologic abnormalities (eosinophilia > 1500/mm$^3$ and presence of atypical lymphocytes)
- systemic involvement:
  - adenopathy (> 2 cm in diameter)
  - hepatitis (transaminase elevation at least twice the normal values)
  - interstitial nephritis
  - pneumonitis
  - carditis.

A Japanese group that investigated severe cutaneous adverse reactions to drugs (SCAR-J) adopted other criteria [8], as presented in Table 1. However, universal adoption of the Japanese criteria may be limited, since one of the criteria is the viral replication during the course of infection, and some tests, such as measurement of IgG titer anti-HHV-6, are not yet routinely available in all hospitals or laboratories.

Differential diagnoses include other skin eruptions induced by drugs, e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis, which are characterized by diffuse small vesicles and purpuric rash.

**TREATMENT**

The early recognition of adverse drug reaction and withdrawal of the offending drug is an essential step toward clinical improvement. Empirical treatment with antibiotics or anti-inflammatory drugs should not be administered during the acute disease as they may confuse or worsen the clinical picture of patients due to an unexplained cross-reactivity between drugs [8].

For many years, the treatment of DRESS was based on systemic glucocorticoids (dose ≥ 1 to 1.5 mg/kg/day of prednisone or equivalent) which lead to a marked amelioration of symptoms and laboratory parameters several days after the start of treatment [8,20,22]. If symptoms get worse despite the use of oral corticosteroids, other options reported in case series are pulsed methylprednisolone (30 mg/kg/day intravenously for 3 days), intravenous immunoglobulin [33], and plasmapheresis, or a combination of these [8]. It should be remembered that the immunosuppressive therapies may increase the risk of infectious complications and sepsis.

Cases of mild disease can be resolved simply by withdrawal of the drug and supportive treatment after a few weeks, even without the use of corticosteroids.

The French Society of Dermatology published the results of a consensus of experts on the therapeutic management of DRESS/DIHS [34]:

- absence of signs of severity: topical glucocorticoids (potent or very potent), emollients, H1-antihistamines
- presence of signs of severity (transaminases > 5 times normal renal organic, pneumonia, hemophagocytosis, cardiac, etc.): glucocorticoids equivalent to 1 mg/kg per day of prednisone, and multidisciplinary evaluation
- life-threatening signs (hemophagocytosis with bone marrow failure, encephalitis, severe hepatitis, renal failure, respiratory failure): steroids generally associated with IVIG at a dose of 2 g/kg over 5 days. IVIG should not be proposed

**Features of DRESS/DIHS include hypogammaglobulinemia, clonal expansion of regulatory T cells and prominence of cytotoxic T cells, leading to autoimmunity**

<table>
<thead>
<tr>
<th>Table 1. Diagnostic criteria for DRESS/DIHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maculopapular rash develops 3 weeks after start of therapy with a limited number of drugs</td>
</tr>
<tr>
<td>2. Persistent clinical findings after drug withdrawal</td>
</tr>
<tr>
<td>3. Fever (≥ 38°C)</td>
</tr>
<tr>
<td>4. Hepatic abnormalities (alanine aminotransferase &gt; 100 U/L)</td>
</tr>
<tr>
<td>5. Leukocyte abnormalities (at least one of the following)</td>
</tr>
<tr>
<td>6. HHV-6 reactivation</td>
</tr>
<tr>
<td>7. Lymphadenopathy</td>
</tr>
</tbody>
</table>

* This can be replaced by other organ involvement such as renal involvement.† Reactivation is detected from the second to third week after symptom onset, through IgG anti-HHV-6 titer elevation.
without associated steroids. These treatments must be conducted through multidisciplinary evaluation

- presence of signs of severity with confirmation of a major viral reactivation: combination of steroids and antiviral agents (ganciclovir) and/or IVIG.

**CONCLUSION**

DRESS/DIHS is a challenging drug adverse reaction where the drug, the immune system and reactivation of previous viral infections may interact causing a life-threatening condition. Clinicians must be alert to this possibility in order to reach the correct diagnosis and institute the appropriate management.

**Corresponding author:**
Dr. P.R. Criado
Rua Carneiro Leão 33, Vila Scarpetti - Santo André, São Paulo – Brazil 09050-430
email: prcriado@uol.com.br

**Acknowledgment**
J.F. Carvalho received grants from Federico Foundation and CNPq (300665/2009-1)

**References**